Tripos Muse 1.0.1 | 154 MB
Tripos International, a leading provider of drug discovery informatics products and services, today announced a collaboration agreement withAstraZeneca to develop a new drug discovery workflow solution.
Tripos International, a leading provider of drug discovery informatics products and services, today announced a collaboration agreement with
The centerpiece of the collaboration effort will be the development of Tripos' new Muse™ de novo design product, which is targeted for commercial release in the fourth quarter of 2008. Muse, which will be designed to accelerate the identification and optimization of lead candidates, will combine de novo design with multi-criteria optimization to deliver the first of many solutions being prepared for release on Tripos' highly flexible, adaptable and extensible Pantheon™ platform.Tripos' Muse Product Manager and Senior Scientist Brian Masek, Ph.D. added, "I'm excited about our collaboration with AstraZeneca and am optimistic that our versatile Pantheon platform will enable Muse to provide the powerful attributes we see emerging from this collaboration. The combination of Tripos' and AstraZeneca's technologies have already helped their drug discovery efforts and this collaboration will allow us to further those achievements and, importantly, to make this science available across the industry."
Commenting on the agreement, James R. Empfield, Director of Lead Optimization Chemistry at AstraZeneca, said, "It's important to consider multiple parameters when defining the characteristics of a successful lead or drug candidate. For example, during the lead identification and optimization processes, factors including biological potency and selectivity and ADME properties must be considered. We look forward to enhancing these capabilities through our collaboration with Tripos."
Jim Damewood, Principal Scientist II with AstraZeneca, added, "Merging AstraZeneca and Tripos capabilities in this area has the potential to provide a powerful and unique capability in ligand-based de novo design."
It is anticipated that Muse will permit researchers to find structures, scaffolds, or side-chains that meet specific design objectives. Integration with other CAMD software will allow for multiple design criteria to be applied. Modelers will be able to quickly and easily generate ideas for new side chains that optimize a panel of biological and ADME properties, preserve key R-groups and invent new scaffolds.
Tripos' General Manager, Patrick Flanagan, adds, "We are confident that the combination of technology and real world insight gained through our efforts with AstraZeneca will bring a unique product to our constituents. We believe that our collective efforts will offer discovery scientists the ability to leverage the robust modeling software of Tripos with the drug development expertise and experience of AstraZeneca to offer an easy to use software tool for candidate design."
Commenting on the agreement, James R. Empfield, Director of Lead Optimization Chemistry at AstraZeneca, said, "It's important to consider multiple parameters when defining the characteristics of a successful lead or drug candidate. For example, during the lead identification and optimization processes, factors including biological potency and selectivity and ADME properties must be considered. We look forward to enhancing these capabilities through our collaboration with Tripos."
Jim Damewood, Principal Scientist II with AstraZeneca, added, "Merging AstraZeneca and Tripos capabilities in this area has the potential to provide a powerful and unique capability in ligand-based de novo design."
It is anticipated that Muse will permit researchers to find structures, scaffolds, or side-chains that meet specific design objectives. Integration with other CAMD software will allow for multiple design criteria to be applied. Modelers will be able to quickly and easily generate ideas for new side chains that optimize a panel of biological and ADME properties, preserve key R-groups and invent new scaffolds.
Tripos' General Manager, Patrick Flanagan, adds, "We are confident that the combination of technology and real world insight gained through our efforts with AstraZeneca will bring a unique product to our constituents. We believe that our collective efforts will offer discovery scientists the ability to leverage the robust modeling software of Tripos with the drug development expertise and experience of AstraZeneca to offer an easy to use software tool for candidate design."